Innate Pharma

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 455
Lid geworden op: 30 mei 2018 21:25
waarderingen: 164
Contacteer:

Re: Innate Pharma

Bericht door And its gone! » 11 nov 2019 15:26

BUZZ-Innate Pharma set for record high as Street starts with "buy"
14:40 (11/11) - Bron: Reuters
** U.S.-listed shares of France-based drugmaker up
3.7% at $6.54 premarket, on pace to hit a record high, as three
brokerages begin coverage with "buy" or equivalent ratings
** IPHA is "a leading first-in-class/novel oncology company"
using monoclonal antibodies, a type of immunology-based therapy
targeting cancer, writes Evercore ISI, setting a PT of $17.50
** SVB Leerink sets PT of $10, says decision to buy
Lumoxiti, an FDA-approved drug targeting leukemia, is sensible
** While investors should not expect a take-out, IPHA's
strategy of focusing on treating rare blood disorders should
allow it to build a targeted franchise - brokerage
** Of particular focus for brokerages was IPHA's
experimental drug monalizumab that target cancers, and which is
expected to enter a pivotal trial in 2020 in partnership with
AstraZeneca AZN.L
** Only 1 of the 7 brokerages covering the stock recommend
"hold", while the rest rate it "buy" or higher
** Through Friday close, stock up only 4.3% since debut on
Oct. 17


(Reporting by Ruhi Soni)
((Ruhi.Soni@thomsonreuters.com;))
Stofke liked last!



powered by Surfing Waves

besportie
Forum veteraan
Forum veteraan
Berichten: 1108
Lid geworden op: 13 feb 2012 18:07
waarderingen: 253
Contacteer:

Re: Innate Pharma

Bericht door besportie » 13 nov 2019 11:23

Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni
$79.1 million (€71.4 millionii) in gross proceeds from our IPO on the Nasdaq and Global Offering
Monalizumab to advance to Phase III clinical trial in combination with cetuximab in IO-pretreated SCCHN patients
Encouraging IPH5401 (anti-C5aR) dose-escalation data supports program advancement in HCC and NSCLC
Lumoxiti commercial transition and filing for EU regulatory approval is on track


Marseille, France, November 13, 2019, 7:00 AM CET

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today announced its revenues and cash position for the first three-months of 2019.

“We have made great strides this year, particularly in the third quarter as we witnessed two major achievements that will continue to propel the company forward,” said Mondher Mahjoubi, Chief Executive Officer, Innate Pharma (IPHYF). “With our partner AstraZeneca, we have decided to advance monalizumab to a Phase III clinical trial, which we believe validates our novel approach to immuno-oncology, and progresses a potential new treatment for head and neck cancer patients. And secondly, the execution of our Nasdaq listing in the US marks a critical step in raising the company’s global profile and supporting our long-term strategy of becoming a global leader in immuno-oncology.”

“With the completion of our Nasdaq IPO, we have strengthened our financial position and strategically broadened our US and global institutional shareholders,” said Laure-Helene Mercier, Chief Financial Officer, Innate Pharma. “With these proceeds, we are well capitalized to fund our maturing and broadening pipeline and to support our operational and commercial expansions in the United States. This year we have successfully focused on executing both clinically and corporately, and we now look forward to further advancing our programs and delivering multiple data read outs in 2020 and 2021.”



Third quarter 2019 and recent pipeline highlights:

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:

Innate announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a Phase III randomized clinical trial evaluating monalizumab in combination with cetuximab in patients suffering from recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have been previously exposed to an immune checkpoint inhibitor (IO-pretreated), and the companies will co-fund the trialiii. The trial initiation is expected in 2020, subject to regulatory and compliance approvals.
At the ESMO 2019 Congress (CACOX), Innate provided long-term follow-up update on the 40 patients of the Phase II study of monalizumab in combination with cetuximab in patients with R/M SCCHN.
Median overall survival of 8.5 months (14.1 months in the IO-pretreated patients and 7.8 months in IO-naïve patients) with median follow-up time of 17 months;
12-month overall survival rate of 44% (60% in IO-pretreated and 32% in IO naïve patients).
Cohort expansion 2 is evaluating the combination of monalizumab and cetuximab in IO-pretreated patients with R/M SCCHN. Recruitment began in September 2018 and the 40 patients are now fully enrolled. Innate expects to report preliminary data from the second cohort expansion in the first half of 2020.
Cohort expansion 3 evaluating the combination of monalizumab, cetuximab and durvalumab in IO-naive patients with R/M SCCHN started in April 2019. Preliminary data are expected in the second half of 2020.
IPH5401 (anti-C5aR antibody):

·At the ESMO 2019 Congress, Innate presented encouraging data from the STELLAR‑001 dose-escalation study. The combination of IPH5401 and durvalumab was well tolerated. No dose limiting toxicity was reported and no dose relationship was observed regarding safety.

Twelve patients were evaluated for efficacy. Early activity signals were observed in HCC and NSCLC patients, both tumor types correlated to high expression of the C5a receptor. One confirmed partial response was reported in a HCC patient with prior progression after nivolumab and one prolonged stable disease (40 weeks) was reported in a NSCLC patient with prior progression after nivolumab;
Additional in vitro data describing the mechanism of action was presented at the SITC 2019 Congress in early November.
·IPH5401 and durvalumab combination expansion cohorts were initiated in patients with IO-pretreated non-small-cell lung cancer (NSCLC) and IO-naïve hepatocarcinoma (HCC), as provided by the protocol. The Company plans to add an additional cohort testing IPH5401 in combination with durvalumab in IO-pretreated HCC patients, subject to regulatory approval. Preliminary data from the first two expansion cohorts is expected in the second half of 2020.

Lumoxiti, a First-in-Class marketed product in-licensed from AstraZeneca for the Treatment of Relapsed or Refractory (R/R) Hairy Cell Leukemia:

Innate continued to progress in establishing a specialized US medical affairs and commercial teams. During the fourth quarter, the US team of approximately 15 field-facing professionals completed the transition of all commercialization activities from AstraZeneca. Per the agreement, Innate remains on track for the full transition of the Lumoxiti BLA to Innate from AstraZeneca by mid-2020.

The submission to file for the European Union regulatory approval of Lumoxiti for the treatment of patients with R/R HCL by AstraZeneca is on track and expected by the end of 2019. Upon the submission, AstraZeneca is eligible to receive a regulatory milestone of $15 million.
Various Preclinical and Drug Discovery:

Innate announced the publication of a Nature review article, “Harnessing Innate Immunity in Cancer Therapy,” authored by Innate Pharma scientists in partnership with other leading scientists. The peer-reviewed article focuses on cancer-immune interactions that now place innate immune cells as critical players in the fight against cancersiv.
At the SITC 2019 Congress, Innate discussed its expertise in immuno-oncology drug discovery with the preclinical data presentations on IPH5401, IPH5201 (anti-CD39) and IPH5301 (anti-CD73), which target the adenosine immunosuppressive pathway, and the Company’s new proprietary trifunctional NK cell engagers (NKCEs).
Post-period events:

In October, Innate Pharma successfully completed its global offering, including its initial public offering on the Nasdaq Global Select Market raising approximately $79.1 million (€71.4 millionv) in gross proceeds from the sale of American Depositary Shares (ADS) in the United States and a European Private Placement of ordinary shares. The global offering resulted in the issuance of 14,375,000 new ordinary shares, comprising 9,922,227 ADSs, at an offering price of $5.50 per ADS, and 4,452,773 ordinary shares in a concurrent European private placement (including France) at an offering price of €4.97 per ordinary share. Each ADS represents one ordinary share.
IPH5401 and durvalumab combination expansion cohorts were initiated in patients with IO-pretreated non-small-cell lung cancer (NSCLC) and IO-naïve hepatocarcinoma (HCC), as provided by the protocol. The Company plans to add an additional cohort testing IPH5401 in combination with durvalumab in IO-pretreated HCC patients, subject to regulatory approval. Preliminary data from the first two expansion cohorts is expected in the second half of 2020.
Innate announced the publication of a Nature review article, “Harnessing Innate Immunity in Cancer Therapy”, authored by Innate Pharma scientists in partnership with other leading scientists. The review article focuses on cancer-immune interactions that now place innate immune cells as critical players in the fight against cancersvi.
At the SITC 2019 Congress, Innate showcased its expertise in immuno-oncology drug discovery with the preclinical data presentations on IPH5401, IPH5201 (anti-CD39) and IPH5301 (anti-CD73) targeting the adenosine immunosuppressive pathway and the Company’s new proprietary trifunctional NK cell engagers (NKCEs).
Financial results:

Cash, cash equivalents and financial assets of the Company amounted to €215.2 million as of September 30, 2019. At the same date, financial liabilities amounted to €18.3 million, of which €0.9 million resulting from the application of IFRS 16vii (€4.9 million as of September 30, 2018). The proceeds from the October global offering are not included.

The increase in cash, cash equivalents, and financial assets is mainly a result of the below:

The collection in July 2019 of the research tax credit relating to the fiscal year 2018 (€13.5m)viii; and
The draw down in August 2019 of the remaining portion of €13.9 million of the €15.2 million loan granted in July 2017 by Société Générale, thereby also increasing the financial liabilitiesix.
Revenues for the first nine-months of 2019 amounted to €65.4 million (€21.8 million for the same period in 2018). For the nine-month period ended September 30, 2019, revenue from collaboration and licensing agreements mainly results from the spreading of the initial payments received under our agreements with AstraZeneca.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of NK cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

bron: seeking alpha
Steven DC liked last!
Turbo long Galapagos,UCB, Argen-x , PostNL / Aandelen: Akebia, Arcadia, Ocul, Acacia / Turbo short Proximus

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 455
Lid geworden op: 30 mei 2018 21:25
waarderingen: 164
Contacteer:

Re: Innate Pharma

Bericht door And its gone! » 13 nov 2019 17:50

BRIEF-Innate Pharma Reports End-Sept Cash At 215.2 Million Euros
08:31 (13/11) - Bron: Reuters
Nov 13 (Reuters) - INNATE PHARMA SA IPH.PA :
* INNATE PHARMA THIRD QUARTER 2019 REPORT
* Q3 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY
AMOUNTED TO EUR 215.2 MILLION

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))

Marbull
Forum gebruiker
Forum gebruiker
Berichten: 113
Lid geworden op: 17 sep 2018 16:14
waarderingen: 15
Contacteer:

Re: Innate Pharma

Bericht door Marbull » 27 nov 2019 19:03

Stilaan terug naar de 6, ziet er veel belovend uit voor 2020
Innate Pharma, Genfit, Galapagos, Inventiva,Celyad, Quantum G, Pharnext

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 455
Lid geworden op: 30 mei 2018 21:25
waarderingen: 164
Contacteer:

Re: Innate Pharma

Bericht door And its gone! » 27 nov 2019 20:10

Marbull schreef:
27 nov 2019 19:03
Stilaan terug naar de 6, ziet er veel belovend uit voor 2020
Daar zeg je het stilaan.
Amerikaanse IPO ook niet direct een spetterend succes te noemen, zou al rond de 10€ moeten noteren, maar raakt met veel moeite over de 6.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 455
Lid geworden op: 30 mei 2018 21:25
waarderingen: 164
Contacteer:

Re: Innate Pharma

Bericht door And its gone! » 03 dec 2019 14:33

Het zal eerder naar de 5€ gaan.
Onder de 5€ mogelijk wat bijkopen :D

Marbull
Forum gebruiker
Forum gebruiker
Berichten: 113
Lid geworden op: 17 sep 2018 16:14
waarderingen: 15
Contacteer:

Re: Innate Pharma

Bericht door Marbull » 04 dec 2019 12:17

Ja?? :!: geduld, een mooie deugd. Beleggen die je met geld dat je niet dadelijk nodig hebt... Ik heb ruim jaar tijd, geen enkele bank geeft u die rente...
Innate Pharma, Genfit, Galapagos, Inventiva,Celyad, Quantum G, Pharnext

besportie
Forum veteraan
Forum veteraan
Berichten: 1108
Lid geworden op: 13 feb 2012 18:07
waarderingen: 253
Contacteer:

Re: Innate Pharma

Bericht door besportie » 04 dec 2019 22:14

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar:

March 10, 2020: Publication of 2019 financial statements, with management comments.

May 12, 2020: Publication of revenue for 1Q2020, with management comments.

May 19, 2020: Annual General Shareholders Meeting.

September 8, 2020: Publication of financial statements as of June 30, 2020, with management comments.

November 17, 2020: Publication of revenue for 3Q2020, with management comments.
Turbo long Galapagos,UCB, Argen-x , PostNL / Aandelen: Akebia, Arcadia, Ocul, Acacia / Turbo short Proximus

bertje
Forum elite
Forum elite
Berichten: 5492
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1143
Contacteer:

Re: Innate Pharma

Bericht door bertje » 08 dec 2019 15:12

Op zondag uitpakken met nieuws,ze moeten er veel van verwachten.

December 8, 2019

Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine.

The final analysis showed that 36 percent (29/80) of the relapsed or refractory hairy cell leukemia patients achieved durable complete response (CR) with Lumoxiti at Day 181 of patients’ respective evaluation, compared to the primary analysis in which 30 percent durable CR rate was reported. In addition, there was a 61 percent probability that patients who achieved a CR would maintain it after five years.

“Lumoxiti is a first-in-class medicine and the only treatment approved in the US for relapsed or refractory hairy cell leukemia in more than twenty years; therefore, it is important for the hematology-oncology community to receive additional analysis of its long-term efficacy,” commented Pierre Dodion, MD, Executive Vice President and Chief Medical Officer of Innate Pharma. “We are grateful to the patients and health care professionals who participated in the clinical development of Lumoxiti and we are passionate about continuing to address the unmet need in this rare form of cancer.”

The single-arm, multi-center, open-label Phase III ‘1053’ clinical trial assessed the efficacy, safety, immunogenicity and pharmacokinetics of Lumoxiti monotherapy in 80 patients with relapsed or refractory hairy cell leukemia who had received at least two prior therapies, including one purine nucleoside analog. The primary endpoint of durable CR was defined as CR with hematologic remission (HR) for >180 days.

Findings from the final analysis of the Lumoxiti Phase III trial include:
Efficacy measure Result* (n=80, 95% Confidence Interval)
Durable CR (CR with HR > 180 days) 36.3% (25.8 to 47.8)
CR with HR ≥ 360 days 32.5% (22.4 to 43.9)
CR rate 41.3% (30.4 to 52.8)
CR with MRD-negative status 33.8% (23.6 to 45.2)
Partial Response Rate 33.8%
Hematologic Remission Rate 80.0%
Median duration of CR 62.8 months (0.0+ to 62.8)
Median Progression-Free Survival 41.5 months (range 0.0+ to 71.7)

* BICR = blinded independent central review

“A key treatment goal for patients with relapsed or refractory hairy cell leukemia is to achieve sustained remission, which can be particularly challenging in patients in whom prior therapies have failed. This long-term analysis demonstrates that Lumoxiti achieved a high rate of durable efficacy, while maintaining the benefit risk profile we saw in the primary analysis,” said Robert J. Kreitman, MD, Senior Investigator, Head of Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, and Principal Investigator of the Phase III clinical trial.

The final analysis shows that the risk-benefit profile of Lumoxiti is maintained. There were no new serious adverse events and no change in hemolytic uremic syndrome or capillary leak syndrome. Per the primary analysis on the 1053 study, the most frequent treatment-related adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), headache (33%), and pyrexia (31%). Treatment-related grade 3/4 AEs were reported in 24 patients (30%) and treatment-related serious AEs in 14 patients (18%). Grade 3/4 CLS events occurred in two patients (2.5%) and any grade of HUS occurred in six patients (7.5%). CLS and HUS events were manageable and reversible with appropriate supportive care and monitoring.

Treatment-emergent AEs led to study drug discontinuation in eight patients (10.0%): hemolytic uremic syndrome (HUS), n = 4 (5.0%); capillary leak syndrome (CLS), n = 2 (2.5%); increased blood creatinine, n = 2 (2.5%); renal failure, n =1 (1.3%); vomiting, n =1 (1.3%); and chills, n =1 (1.3%). There were four deaths reported (including the three reported during the primary analysis): two due to disease progression and two due to an AE (1 each of pneumonia and septic shock). No death was considered treatment related.

About Lumoxiti (moxetumomab pasudotox-tdfk):

Lumoxiti is a CD22-directed immunotoxin and a first-in-class treatment in the US for adult patients with relapsed or refractory (r/r) hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min). It comprises the CD22 binding portion of an antibody fused to a truncated pseudomonas exotoxin. The toxin inhibits protein synthesis and ultimately triggers apoptotic cell death. Lumoxiti received U.S. FDA approval in September 2018 and has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for the treatment of r/r HCL. AstraZeneca is the current Biologics License Application (BLA) holder for Lumoxiti.

About the ‘1053’ Phase III trial:

The approval of Lumoxiti was based on data from the AstraZeneca-sponsored, open-label ‘1053’ trial, which was a single-arm, multi-center Phase III clinical trial assessing the efficacy, safety, immunogenicity and pharmacokinetics of Lumoxiti monotherapy in patients with r/r HCL who have received at least two prior therapies, including one purine nucleoside analog. The trial enrolled 80 patients and was conducted across 34 sites in 14 countries. The primary endpoint was durable complete response (CR), defined as CR with hematologic remission (blood count normalization) for more than 180 days. Secondary endpoints included overall response rate, relapse-free survival, progression-free survival, time to response, safety, pharmacokinetics and immunogenic potential.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:
ISIN code
Ticker code
LEI FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s final prospectus dated October 16, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:
Investors



Innate Pharma

Danielle Spangler / Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

Media



Innate Pharma

Tracy Rossin (Global/US)

Tel.: +1 240 801 0076

Tracy.Rossin@innate-pharma.com



ATCG Press

Marie Puvieux (France)

Tel.: +33 (0)9 81 87 46 72

innate-pharma@atcg-partners.com


Attachment

191208 ASH data press release EN
And its gone! liked last!

Marbull
Forum gebruiker
Forum gebruiker
Berichten: 113
Lid geworden op: 17 sep 2018 16:14
waarderingen: 15
Contacteer:

Re: Innate Pharma

Bericht door Marbull » 08 dec 2019 21:04

Benieuwd voor opening morgen :up:
Innate Pharma, Genfit, Galapagos, Inventiva,Celyad, Quantum G, Pharnext

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. 
Registreer binnen enkele tellen



Plaats reactie